DNA Marker, Post BMT Engraftment, Tissue


Sunquest Code:PSTTMDCoPath Code:PSTENFTTS
  Epic Name:Post BMT Engraftment Analysis, Tissue
Sunquest Code (non-Epic sites):MD  
Order Instructions:For blood, use Sunquest code: PSTNFT, CoPath Code: POSTENFT (B) For bone marrow use Sunquest Code: PENTBM, CoPath Code: POSTENFT (BM)
Synonyms:Bone Marrow Transplant DNA Marker; Bone Marrow Transplant Engraftment Evaluation; Molecular; Post BMT Chimerism Study; RLFP
Methodology:Amplification of DNA and detection by capillary electrophoresis
CPT Code:----------CPTCODES HERE----------
Test Includes:BMT DNA processing, DNA marker, post BMT engraftment
Turnaround Time:Performed Mon-Fri; results are reported within 3 days.


Collection Instructions

Specimen:Tissue
Optimal Volume:3 mm x 3 mm x 3 mm fresh tissue, embedded tissue (sufficient for 10-20 five micron sections)
Minimum\Peds Volume:2 mm x 3 mm x 3 mm fresh tissue, embedded tissue (sufficient for 5-10 five micron sections)
Collection Instructions:
  • Fresh tissue: Collect in sterile container. Deliver to the laboratory within 1 hour or freeze specimen (liquid nitrogen or dry ice) and transport to the laboratory frozen (-70°C or place in RPMI and transport same day at 4°C.
  • Paraffin embedded tissue: Indicate fixative used. Ship at room temperature.
Causes for Rejection:Sample not processed correctly; see Collection Instructions. Add on testing to hematology samples is not accepted. Decalcified tissue.  DNA extracted at non-CLIA certified (or equivalent) lab.


Processing and Shipping

Specimen Processing:Do not process.
Shipping Instructions:Ship fresh tissue to arrive at laboratory within 1 hour at room temperature. Alternatively, freeze sample (see Collection Instructions) and transport within 24 hours. Ship paraffin embedded tissue at room temperature. Specimens received after 1400 Fri-Sun will not be processed until Mon.
Test Performed at or Referral Lab Molecular Diagnostics 


Interpretive

Reference Range:By report.
Use:Allogeneic hematopoietic cell transplant (HCT) is a therapeutic option available for treatment of numerous malignancies and inherited genetic disorders. Monitoring engraftment following allogeneic HCT is necessary for early documentation of engraftment, detection and timely treatment of graft rejection or early relapse. The presence of lymphohematopoietic cells of donor origin after allogeneic HCT is referred to as "chimerism". The kinetics of engraftment in different cell populations has been found to be different among T cells, Natural Killer (NK) cells, granulocytes and monocytes. Generally donor T cell chimerism has been found to lag behind donor myeloid chimerism. Early patterns of T and NK cell chimerism have predicted patients at increased risk of graft rejection and graft versus host disease. Hence lineage-specific chimerism (i.e., monitoring of engraftment is specific subset) may provide valuable clinical information in identifying patients at high risk for adverse clinical events.


Click HERE to Report test errors or omissions.
*If no email program is associated with this computer, please contact:
systemlabguide@fairview.org for TestID: 4860"